UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...
Diwas Budhathoki, the dedicated Pokemon aficionado, is your guide into the Pokemon franchise. His eSports writing journey began years ago, and he's been sharing his passion through GameRant since ...
UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...
Dapirolizumab pegol demonstrated significant efficacy in reducing fatigue and disease activity in systemic lupus erythematosus patients during the PHOENYCS GO study. Dapirolizumab pegol (DZP), a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback